Get the Daily Brief
Latest Biotech News
Regulatory and trial decisions in oncology
Novartis moved to exit its Fabhalta (iptacopan) lupus nephritis program, terminating a mid-stage trial cited as “strategic considerations” in a federal clinical trials database. The decision...
EU approval for oral GLP-1 expands obesity pipeline
Eli Lilly won European Medicines Agency human medicines committee (CHMP) endorsement for its oral GLP-1 pill orforglipron, positioning the drug to challenge Novo Nordisk’s oral Wegovy franchise....
AI drug discovery funding and IPO activity
Iambic Therapeutics priced an IPO after raising $150 million to expand clinical development for its AI-discovered oncology pipeline. The company’s CEO framed AI as a means to convert molecular...
Large biotech financing for gene therapy in inherited kidney disease
Estuary Biotherapeutics raised $103 million to advance preclinical gene therapy candidates targeting inherited kidney disease, describing two programs built for the most common disorder in the...
IPO wave in RNAi drug development
City Therapeutics priced a $200 million IPO to fund an RNAi pipeline framed as “Alnylam 2.0,” highlighting tissue delivery beyond the liver as an ongoing focus. The offering supports medicines in...
FDA rare disease regulatory reset framework
The FDA signaled a structural shift in rare disease drug review with a “Rare Disease Framework Initiative,” aiming to improve consistency and seek external advice rather than rely on a...
Clinical update in CAR-T for multiple myeloma
Anito-cel, a BCMA-directed CAR-T candidate, reported responses in all 38 evaluable patients in a phase 1 study of relapsed or refractory multiple myeloma. The dataset also described a favorable...
Funding for AI-enabled target discovery collaboration (AZ + insitro)
AstraZeneca signed a drug discovery and licensing agreement with insitro to apply the Virtual Human platform to metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. The...
Rare disease voucher monetization to fund gene therapy pipeline
Ultragenyx agreed to sell a second rare pediatric Priority Review Voucher (PRV) for $203 million, following a prior voucher sale and after FDA approval of FAYUVI (rebisufligene etisparvovec-hopf)....
RNA-based flu vaccine dosing interval improves immunogenicity
A phase 1 trial found that extending the dosing interval improved durability for a self-amplifying mRNA H5N1 vaccine, ARCT-2304. An eight-week interval generated stronger and longer-lasting...
FDA rare-disease review overhaul signals regulatory reset
The FDA outlined a new “Rare Disease Framework Initiative” to change how it regulates rare disease therapies, aiming to move from a one-size-fits-all approach toward standards tailored to...
AI-enabled diagnostics and radiology tools move toward clinical evaluation
Researchers and clinicians reported multiple advances in AI assistance for imaging-based care, including a prospective observer-performance trial in salivary gland tumors and new work on...
Regenerative and gene therapy funding accelerates outside the liver
Two U.K.-linked fundraising updates underscored continued appetite for gene therapy platforms with new indications and delivery strategies. OMass Therapeutics raised $310 million in an...
RNAi dealmaking heats up as Roche expands beyond the liver
Roche struck a deal to license an ALK7-targeting siRNA program from China-based Rona Therapeutics, aiming to expand its RNAi pipeline in obesity and metabolic disease. The agreement includes...
Solid-tumor CAR-T pushes into early clinical readouts
Early clinical data continued to challenge the idea that CAR-T is limited mainly to hematologic cancers, with a Phase 1 report in relapsed/refractory multiple myeloma showing responses across all...
Imaging and decision tools aim to improve cancer surgery selection
New clinical decision-support work focused on aligning surgical choices with patient-reported outcomes, aiming to reduce variability in breast-conserving surgery versus mastectomy decisions....
Vaccines and dosing schedules advance for H5N1 self-amplifying mRNA
A Phase 1 study reported durability differences for an H5N1 self-amplifying mRNA vaccine, with an eight-week dosing interval producing stronger and longer-lasting antibody responses than a...
Microbiology and bloodstream infections highlight risk in high-acuity oncology populations
A global meta-analysis reported high prevalence of vancomycin-resistant Enterococcus among patients with hematological malignancies, including near-universal prevalence among stem cell transplant...
Clinical safety and standards: FDA and evidence-quality pressure continues
Multiple items in today’s feed pointed to increasing emphasis on evidence quality, from regulatory frameworks to clinical decision support and from prospective imaging evaluation to retractions...
Neuro and autoimmune interplay: rare immune toxicities mapped in immunotherapy
A large case series and systematic review mapped a rare but deadly triple immune-related toxicity involving the heart, muscle, and neuromuscular junction in cancer immunotherapy patients. The work...